---
title: Prognostication and risk stratification of patients with myelodysplastic syndromes
date: '2023-08-10'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37562001/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20230811181201&v=2.17.9.post6+86293ac
source: Blood
description: Risk stratification and prognostication are crucial for the appropriate
  management of patients with myelodysplastic syndromes or myelodysplastic neoplasms
  (MDS), for whom expected survival can vary from a few months to more than 10 years.
  For the past five decades, patients with MDS have been classified into higher-risk
  versus lower-risk disease phenotypes using sequentially developed clinical prognostic
  scoring systems. Factors such as morphologic dysplasia, clinical hematologic ...
disable_comments: true
---
Risk stratification and prognostication are crucial for the appropriate management of patients with myelodysplastic syndromes or myelodysplastic neoplasms (MDS), for whom expected survival can vary from a few months to more than 10 years. For the past five decades, patients with MDS have been classified into higher-risk versus lower-risk disease phenotypes using sequentially developed clinical prognostic scoring systems. Factors such as morphologic dysplasia, clinical hematologic ...